Jeil Pharm (002620) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Jeil Pharm KRW 20,974, price KRW 7,500, upside +179.7%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Jeil Pharm for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range 6,290 KRW – 24,969 KRW · fair‑value band 15,609 KRW – 26,218 KRW · the 7,500 KRW price screens below the 20,974 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.
Follow Jeil Pharm in your weekly email
Every Wednesday you see whether Jeil Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products.
Show more
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.
Stock analysis
Jeil Pharm (002620) currently trades at 7,500 KRW, while our model-based Fair Value estimate is 20,974 KRW, implying the stock looks roughly 64.2% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 50,615 KRW per share, and 15 of the 17 models we run sit above the 7,500 KRW price.
Bear case: the Asset-Based group reads lowest at 13,911 KRW, and 2 of the 17 models stay below the price. Evidence for this calculation is low.
Scenario range: 15,609 KRW (bear) to 26,218 KRW (bull), the price of 7,500 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Jeil Pharm reported revenue of 658B KRW in FY2025 versus 763B KRW in FY2021, a compound −3.6%/yr. Reported net income was 14.6B KRW in FY2025.
Key figures
Market cap 115B KRW (≈ $80.6M) · P/S ratio 0.16 · Dividend yield 0.9% · Net margin 2.2% · Return on equity 7.5% · Return on assets (EBIT) 0.7% · Operating margin 2.4% · Revenue (TTM) 626B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 180%, 002620 screens cheaper than that median.
Fair Value models
Bear 15,609 KRWFair Value 20,974 KRWBull 26,218 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Start year 2020 (pandemic). Over 10 years: +1.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
’11
’12
’15
’16
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+6.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.1%
Dividend (yield on the price)0.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 6%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 614 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jeil Pharm Fair Value". https://www.fairvalue-calculator.com/stock/002620.KO
Frequently asked questions
Is Jeil Pharm (002620) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 20,974 KRW versus a price of 7,500 KRW, about +180% upside (undervalued).
What is the fair value of 002620?
Our model-based fair value for Jeil Pharm is 20,974 KRW (as of Sep 23, 2026), built from audited fundamentals. The current price: 7,500 KRW.
What is the quality score of 002620?
Jeil Pharm has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jeil Pharm (002620)?
Our model-based price target is the fair value of 20,974 KRW (as of Sep 23, 2026) from 17 valuation models. Cautious scenario 15,609 KRW, optimistic scenario 26,218 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Jeil Pharm stock forecast for 2026?
Our models put fair value at 20,974 KRW, about +180% upside versus a price of 7,500 KRW (undervalued). Cautious scenario 15,609 KRW, optimistic scenario 26,218 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Jeil Pharm (002620)?
Jeil Pharm reported trailing-twelve-month revenue of about 626B KRW (latest available figure, as of Sep 23, 2026).
Does Jeil Pharm pay a dividend?
Jeil Pharm currently shows a dividend yield of about 0.93% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Jeil Pharm (002620)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jeil Pharm it is 20,974 KRW per share (as of Sep 23, 2026), against a price of 7,500 KRW. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Jeil Pharm stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 002620 trades below its calculated fair value: price 7,500 KRW, fair value 20,974 KRW, a gap of about +180% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002620?
No. The price is what the market pays today (7,500 KRW); the fair value is what the company's own numbers justify (20,974 KRW). For Jeil Pharm the two are 13,474 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Jeil Pharm worth?
The market values Jeil Pharm at about 115B KRW (market capitalisation, as of Sep 23, 2026). Per share that is 7,500 KRW; our models calculate a fair value of 20,974 KRW per share.
What do the bullish and bearish scenarios say about 002620?
Our models span a range for Jeil Pharm: cautious scenario 15,609 KRW, base 20,974 KRW, optimistic 26,218 KRW per share (as of Sep 23, 2026, price 7,500 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jeil Pharm (002620)?
Balance-sheet figures for Jeil Pharm (as of Sep 23, 2026): return on equity 7.5%, debt of 0.05 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 002620 from its 52-week high?
Jeil Pharm trades at 7,500 KRW, about 24% below its 52-week high of 9,850 KRW and 9% above the low of 6,860 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 20,974 KRW is for.
Which stocks are comparable to Jeil Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jeil Pharm stock attractive at the current price?
The data as of Sep 23, 2026: price 7,500 KRW, calculated fair value 20,974 KRW (+180%), Quality Score 47/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002620 calculated?
We run Jeil Pharm through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 20,974 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Jeil Pharm currently trades 180 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jeil Pharm (002620)?
The closing price on Sep 23, 2026 was 7,500 KRW. Our model-based fair value is 20,974 KRW, about +180% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jeil Pharm right now?
The price is below even our cautious bear case (15,609 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Jeil Pharm
How large is the market capitalisation of Jeil Pharm (002620)?
The market capitalisation of Jeil Pharm is 115B KRW (≈ $80.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jeil Pharm (002620)?
The price-to-sales ratio of Jeil Pharm is 0.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Jeil Pharm (002620)?
The dividend yield of Jeil Pharm is 0.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jeil Pharm (002620)?
The net margin of Jeil Pharm is 2.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jeil Pharm (002620)?
The return on equity (ROE) of Jeil Pharm is 7.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jeil Pharm (002620)?
On an EBIT basis the return on assets of Jeil Pharm is 0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jeil Pharm (002620)?
The operating margin of Jeil Pharm is 2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jeil Pharm (002620)?
Revenue at Jeil Pharm is growing −17.4% versus a year earlier (3y avg −6.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jeil Pharm (002620)?
Earnings per share at Jeil Pharm are growing −52.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jeil Pharm (002620) generate?
The free cash flow of Jeil Pharm is −8.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jeil Pharm (002620) carry?
The net debt of Jeil Pharm is 110B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jeil Pharm in the live analysis
One click puts Jeil Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
